ARCHIVES

FDA Considering Ways To Improve Process Of Secondary Approvals Of Cancer Drugs

This article is from The Cancer Letter archive.

Vol. 17 No. 42 | November 1, 1991

Download PDF Visit The Full Archive

Related Articles

NCI, FDA Are Feuding Again, This Time Overcharge That DCT Moved Too Slowly On Toxicity Notification

April 10, 1981

Clinical Trials Approved By NCI

March 26, 2004

Monroe Wall, Co-Discoverer Of Taxol, Camptothecin, Dead At 85

July 12, 2002

Another Feasibility Study For Women’s Wealth Trial? Yes And No; It’s ‘Class Of 84’s” Adieu

December 14, 1990

Report on Carcinogens: Advisors Recommend Tobacco, UV Light, Tamoxifen, For Report

November 7, 1997

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002